Quiet Altus Pharma Has Big Things in Store
- Loading Comments...
Altus Pharmaceuticals(ALTU Quote) has a novel drug-enhancement technology, two products entering phase III clinical trials, and most recently, a collaboration with one of biotech's biggest players.
But one year after going public, this young biotech firm still keeps a fairly low profile.
If you haven't gotten to know Altus yet, now is a good time, before the phase III trials begin in the second quarter and the news flow gears back up. Altus' lead product, known as ALTU-135, is a pancreatic enzyme-replacement therapy for cystic fibrosis and other diseases.
Highly pure, with more stability and improved convenience and dosing compared with existing products, ALTU-135 should be able to grab a significant chunk of a $600 million to $700 million worldwide commercial opportunity. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,366.15 | 1,099.92 | 2,173.14 | 33.80 |
Oil *
77.94
|
|
DOWN
86.53
|
DOWN
9.32
|
DOWN
11.89
|
UP
0.57
|
10 Yr
3.38%
SPDR Gold
118.70
|
|
-0.83%
|
-0.84%
|
-0.54%
|
+1.72%
|
Data delayed 20 minutes |
Connect with TheStreet